Elevated FSP1 expression confers resistance to GPX4 inhibitor-induced ferroptosis across multiple cancer types, including TNBC, whereas the genetic ablation of FSP1 markedly sensitizes TNBC cells to ferroptosis-inducing agents [11,68]. Here, AIFM2 is linked to cancer.